Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFT505 for Non-Alcoholic Steatohepatitis (NASH)
2012-000295-42Phase 2Completed
- Sponsor
- Genfit
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elafibranor in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Genfit. Started Aug 2012; status: completed.
02
Drugs
elafibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2012-000295-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000295-42.